Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities
Net income	$ (5,089)	$ 22,859
Adjustments to reconcile net income to net cash provided by (used in) operating activities
Net accretion of bond premium	6,969	10,546
Depreciation and amortization	8,079	4,887
Stock-based compensation expense	2,590	3,074
Net investment (gains) losses	35,647	(28,243)
Net cash flows from equity and trading investments	29,725	34,504
Deferred income tax expense (benefit)	(9,224)	248
Changes in:
Accrued investment income	(1,773)	668
Premiums receivable	(57,570)	(7,780)
Deferred policy acquisition costs	(14,930)	(7,966)
Reinsurance receivables	(28,145)	39,250
Prepaid reinsurance premiums	(2,814)	3,653
Income taxes receivable	(7,215)	(2,880)
Other assets	6,758	(8,456)
Losses and loss settlement expenses	(49,757)	(10,481)
Unearned premiums	48,560	(5,914)
Accrued expenses and other liabilities	1,403	(21,348)
Deferred income taxes	0	(1,009)
Other, net	6,993	(7,424)
Cash from operating activities	(24,704)	(4,671)
Net cash provided by (used in) operating activities	(29,793)	18,188
Cash Flows From Investing Activities
Proceeds from sale of available-for-sale investments	83,409	170,637
Proceeds from call and maturity of available-for-sale investments	145,618	214,702
Proceeds from sale of other investments	3,243	3,616
Purchase of investments in mortgage loans	(103)	0
Purchase of investments available-for-sale	(262,359)	(331,644)
Purchase of other investments	(5,447)	(6,021)
Net purchases and sales of property and equipment	(2,675)	(10,932)
Net cash provided by (used in) investing activities	(38,314)	40,358
Cash Flows From Financing Activities
Issuance of common stock	846	(412)
Repurchase of common stock	0	(2,008)
Payment of cash dividends	(11,826)	(11,302)
Net cash used in financing activities	(10,980)	(13,722)
Net Change in Cash and Cash Equivalents	(79,087)	44,824
Cash and Cash Equivalents at Beginning of Period	132,104	87,948
Cash and Cash Equivalents at End of Period	$ 53,017	$ 132,772